BPG is committed to discovery and dissemination of knowledge
Featured Articles
10/13/2021 1:00:01 PM | Browse: 37 | Download: 118
Publication Name World Journal of Gastrointestinal Oncology
Manuscript ID 66656
Country/Territory China
2021-04-15 01:18
Peer-Review Started
2021-04-15 01:21
To Make the First Decision
Return for Revision
2021-06-04 01:04
2021-06-14 18:03
Second Decision
2021-08-16 03:31
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2021-08-16 09:46
Articles in Press
2021-08-16 09:46
Publication Fee Transferred
Edit the Manuscript by Language Editor
2021-08-31 03:45
Typeset the Manuscript
2021-10-08 12:16
Publish the Manuscript Online
2021-10-13 12:57
ISSN 1948-5204 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology and Hepatology
Manuscript Type Prospective Study
Article Title Efficacy and toxicity of capecitabine combined with intensity-modulated radiotherapy after D1/D2 lymph node dissection in patients with gastric cancer
Manuscript Source Unsolicited Manuscript
All Author List Xin Wang, Wei-Hu Wang, Shu-Lian Wang, Yong-Wen Song, Yue-Ping Liu, Yuan Tang, Ning Li, Wen-Yang Liu, Hui Fang, Ye-Xiong Li, Dong-Bing Zhao, Yihebali Chi, Lin Yang and Jing Jin
Funding Agency and Grant Number
Funding Agency Grant Number
Beijing Hope Run Special Fund of Cancer Foundation of China LC2018L03
Sanming Project of Medicine in Shenzhen SZSM201612063
Shenzhen High-level Hospital Construction Fund
Corresponding Author Jing Jin, MD, Doctor, Professor, Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 113 Baohe Avenue, Longgang District, Shenzhen 518116, Guangdong Province, China. jingjin1025@163.com
Key Words Gastric cancer; Radiotherapy; Chemoradiotherapy; Clinical trial; Phase II
Core Tip In our previous phase I study, we found out adjuvant chemoradiotherapy (ACRT) regimen of 45 Gy radiotherapy concurrent with oral capecitabine was well tolerated in patients with locally advanced gastric cancer who had received partial or total gastrectomy. The maximum tolerated dose and recommended dose of capecitabine was 800 mg/m2 twice daily with oral administration. We performed this phase II study to further assess the efficacy and toxicity of this ACRT regimen as an adjuvant therapy after radical resection and D1/D2 lymph node dissection for locally advanced gastric cancer patients.
Publish Date 2021-10-13 12:57
Citation Wang X, Wang WH, Wang SL, Song YW, Liu YP, Tang Y, Li N, Liu WY, Fang H, Li YX, Zhao DB, Chi Y, Yang L, Jin J. Efficacy and toxicity of capecitabine combined with intensity-modulated radiotherapy after D1/D2 lymph node dissection in patients with gastric cancer. World J Gastrointest Oncol 2021; 13(10): 1532-1543
URL https://www.wjgnet.com/1948-5204/full/v13/i10/1532.htm
DOI https://dx.doi.org/10.4251/wjgo.v13.i10.1532
Full Article (PDF) WJGO-13-1532.pdf
Full Article (Word) WJGO-13-1532.docx
Manuscript File 66656-Review-FilipodiaCL.doc
Answering Reviewers 66656-Answering reviewers.pdf
Audio Core Tip 66656-Audio core tip.MP3
Biostatistics Review Certificate 66656-Biostatistics statement.pdf
Clinical Trial Registration Statement 66656-Clinical trial registration statement.pdf
Conflict-of-Interest Disclosure Form 66656-Conflict-of-interest statement.pdf
Copyright License Agreement 66656-Copyright license agreement.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s) 66656-Grant application form.pdf
Signed Informed Consent Form(s) or Document(s) 66656-Informed consent statement.pdf
Institutional Review Board Approval Form or Document 66656-Institutional review board statement.pdf
Non-Native Speakers of English Editing Certificate 66656-Language certificate.pdf
Peer-review Report 66656-Peer-review(s).pdf
Scientific Misconduct Check 66656-Bing-Wang JL-1.jpg
Scientific Misconduct Check 66656-Bing-Wu YXJ-2.jpg
Scientific Misconduct Check 66656-Scientific misconduct check.pdf
Scientific Editor Work List 66656-Scientific editor work list.pdf